Table 2.
The 12 cell lines used for high-throughput cytotoxicity screening. Measured tolerances (IC50 values; μg/mL) to PACA NPs are given as mean value ± standard deviation. The three first cell lines listed were screened only against a subset of NPs. The average IC50 value for prostaste carcinoma cells (DU-145 cells) could not be calculated due to values out of range (>300 μg/mL).
| Cell Lines | Cell Origin | IC50 All NPs (μg/mL), N = 18 |
IC50 PBCA NPs (μg/mL), N = 10 |
IC50 PEBCA NPs (μg/mL), N = 5 | IC50 POCA NPs (μg/mL), N = 3 |
|---|---|---|---|---|---|
| IMR-90 | Lung fibroblast (normal) | 26 ± 19 | 32 ±2 4 | 22 ± 7 | 13 ± 3 |
| Hep G2 | Liver carcinoma | 26 ± 24 | 21 ± 3 | 70 ± 4 | 24 ± 1 |
| RBE4 | Rat brain endothelial cell | 44 ± 29 | 50 ± 5 | 74 ± 15 | 6 ± 1 |
| DU-145 | Prostate carcinoma | - | 30 ± 7 | >300 | 22 ± 8 |
| A498 | Kidney carcinoma | 23 ± 8 | 23 ± 5 | 30 ± 8 | 12 ± 3 |
| SW-620 | Colon adenocarcinoma | 37 ± 19 | 35 ± 7 | 56 ± 20 | 10 ± 3 |
| HOP-92 | Non-small lung carcinoma | 53 ± 45 | 77 ± 46 | 31 ± 7 | 7 ± 1 |
| MDA-MB-468 | Mammary gland adenocarcinoma | 19 ± 11 | 20 ± 9 | 26 ± 10 | 5 ± 1 |
| SF-295 | Glioblastoma multiform | 65 ± 58 | 38 ± 9 | 145 ± 40 | 20 ± 5 |
| UACC-62 | Mammary gland carcinoma | 15 ± 6 | 16 ± 2 | 19 ± 8 | 6 ± 1 |
| OVCAR-3 | Ovarian adenocarcinoma | 15 ± 7 | 15 ± 6 | 18 ± 7 | 8 ± 1 |
| COLO 205 | Colon adenocarcinoma | 23 ± 7 | 22 ± 6 | 31 ± 3 | 13 ± 3 |